[Variants of left ventricular hypertrophy in patients on programmed hemodialysis]

Related Experiment Video

Updated: Sep 28, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

A P Il'in, V F Bogoiavlenskiĭ, R M Gazitov

    Klinicheskaia Meditsina
    |December 11, 2002
    PubMed

    Insights

    Programmed hemodialysis (PHD) effectively treated chronic renal failure (CRF) in most patients. However, left ventricular hypertrophy progression during dialysis indicates a poor prognosis, particularly in older individuals.

    Area of Science:

    • Nephrology
    • Cardiology
    • Medical Technology

    Context:

    • Programmed hemodialysis (PHD) is a treatment for chronic renal failure (CRF).
    • Cardiovascular complications are a major concern in CRF patients undergoing dialysis.
    • Left ventricular hypertrophy (LVH) is a known cardiac adaptation in CRF.

    Purpose:

    • To identify objective prognostic indicators for cardiovascular function in CRF patients undergoing PHD.
    • To compare the development of LVH in younger versus elderly CRF patients on PHD.
    • To assess the impact of dialysis duration on LVH progression and prognosis.

    Summary:

    • PHD was successfully applied to 189 of 207 CRF patients over 10 years.
    • LVH development was studied in young (18-40 years) and elderly (55-73 years) patient groups.
    • Concentric LVH transitioned to eccentric or mixed forms with increased 'dialysis age', indicating a worse prognosis, especially in elderly patients.

    Impact:

    • The study highlights the prognostic significance of LVH progression in PHD patients.
    • Findings suggest closer cardiovascular monitoring for CRF patients, particularly the elderly, undergoing long-term dialysis.
    • Identifying unfavorable prognostic trends like LVH progression can help prevent fatal complications in CRF management.

    More Related Videos

    A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

    A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

    Published on: March 1, 2022

    Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

    Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

    Published on: June 14, 2016

    Related Concept Videos

    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Hemodialysis II: Procedure and Complications01:24

    Hemodialysis II: Procedure and Complications

    DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...